Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Extension Study of Revusiran in Transthyretin-mediated Familial Amyloidotic Cardiomyopathy
2015-005333-49Phase 3Terminated
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Apr 2016
- Modality
- Gene Therapies, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of revusiran in familial amyloid cardiomyopathy (FAC) and familial amyloidosis, sponsored by Alnylam Pharmaceuticals. Primary endpoint: Incidence of adverse events and serious adverse events. Started Apr 2016; status: terminated.
02
Drugs
revusiran
03
Conditions
familial amyloid cardiomyopathy (FAC)familial amyloidosis
Beyond the preview
Go deeper on 2015-005333-49.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005333-49.